The World Council of Churches - Ecumenical Advocacy Alliance endorses a newly expanded collaboration on HIV between the Medicine Patent Pool and Gilead. On 4 October, the MPP announced a licence with Gilead Sciences for bictegravir, a new integrase inhibitor part of a once-daily, single-tablet HIV regimen currently filed for regulatory approval at the United States Food and Drug Administration and the European Union.
11 October 2017
